Title: 1 2 Healthcare Cost of Stargardt Disease 3 **Authors:** 4 Kanza Aziz¹, Bonnielin K. Swenor^{1,2}, Joseph K. Canner³, Mandeep S. Singh^{1*} 5 6 7 **Affiliations:** 8 ¹Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA 9 ²Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA 10 ³Johns Hopkins Surgery Center for Outcomes Research, Johns Hopkins University School of 11 Medicine, Baltimore, MD, USA 12 13 14 *Corresponding author: Address: Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 N. Wolfe 15 16 Street, Baltimore, MD 21287 Email: mandeep@jhmi.edu 17 18 19 20 **Meeting Presentation:** 21 Partial analyses were presented as a poster at the Association for Research in Vision and 22 Ophthalmology Annual Meeting 2018 (published abstract: Aziz et al., Healthcare Costs of 23 Stargardt Disease. Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5221) 24 25 **Financial Support:** Foundation Fighting Blindness (MSS), Joseph Albert Hekimian Fund (MSS), National Institute 26 27 on Aging K01AG052640 (BKS), Research to Prevent Blindness (unrestricted grant to the Wilmer Eye Institute) 28 29 30 **Conflict of Interest:** 31 No conflicting relationship exists for any author 32 33 Word Count: 2315

Abstract

- 35 **Importance:** Stargardt disease (SD) is the most common juvenile macular degeneration and a
- leading cause of uncorrectable childhood blindness. The progressive and incurable nature of this
- 37 chronic condition entails a long-term financial burden on affected individuals. The economic costs
- of SD have not been characterized in detail.
- 39 **Objective:** To estimate the direct healthcare cost of SD.
- 40 **Design:** Cross-sectional analysis of healthcare claims.
- 41 **Participants:** Patients with an ICD-9 diagnosis code of SD, non-exudative age-related macular
- degeneration (AMD), or bilateral sensorineural hearing loss (SHL).
- 43 **Methods:** Outpatient administrative claims data from the IBM® MarketScan® Commercial
- 44 Claims and Encounters Database from 2010 to 2014 were analyzed.
- 45 **Main Outcome Measure:** Annual per-patient direct healthcare cost.
- 46 **Results:** A total of 472,428 patients were analyzed (5,015 SD, 369,750 SHL and 97,663 AMD
- patients respectively). The payment per year of insurance coverage for SD (median: \$105.58, IQR:
- 48 \$50.53-\$218.71) was higher than that of SHL (median: \$51.01, IQR: \$25.66-\$121.66, p < 0.001)
- 49 and AMD (median: \$76.20, IQR: \$38.00-\$164.86, p <0.001). When adjusted for covariates, the
- annual payment for SD was \$47.83 higher than SHL (p<0.001) and \$17.34 higher than AMD
- 51 (p<0.001).
- 52 **Conclusions and Relevance:** There is a significant direct healthcare cost associated with SD. The
- 53 annual per-patient cost of SD was higher than SHL, another condition that causes sensory
- 54 impairment in people of all ages, and nonexudative AMD which causes a similar pattern of visual

- loss that typically begins later in life. The total lifetime per-patient cost of SD may exceed that of
- 56 nonexudative AMD.

Introduction

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

Stargardt disease (SD) is the most common form of inherited macular degeneration, and is caused by mutations in the ABCA4 gene. Its reported incidence is 1 in $8,000 - 10,000^{1}$. People with SD typically begin to experience progressive visual loss as children or young adults². Although there is no cure at present, several possible treatments including pharmacologic, stem cell, and gene therapy modalities are being evaluated in clinical trials^{3,4}. Without treatment, vision loss in SD is typically progressive. Approximately one decade after symptom onset, visual acuity typically reaches the 20/100 to 20/200 level^{5,6}. Management strategies for symptomatic patients currently include disease monitoring, counseling, and low vision rehabilitation. When coupled with the current lack of treatment options, the progressive nature of SD entails long-term healthcare-related financial implications for patients. Furthermore, available data suggest that early-onset SD tends to run a more severe course, and causes severe permanent vision loss earlier in life, than lateronset SD^{3,7}. Those affected by earlier SD onset may require more medical care and therefore incur greater costs. There is a paucity of information on the healthcare costs of SD. Presumably this is because SD is regarded as a rare disease, unlike age related macular degeneration (AMD)^{8,9}. The global AMD treatment market is expected to reach \$11.6 billion by 2026¹⁰. SD is currently the target of therapeutic development; estimates of the healthcare costs associated with SD would be useful in determining the total impact of these therapies. Healthcare costs have significant implications for both the individual and society because these costs constitute an important driving factor behind healthcare policy and economics, especially for chronic diseases such as SD. To better understand healthcare costs associated with SD in the context of other disease conditions, we also analyzed the costs associated with non-exudative AMD and bilateral sensorineural hearing

loss (SHL) as controls. The rationale for selecting non-exudative AMD was that the typical pattern of vision loss during the course of disease is analogous to SD to some degree. The macula is the site of retinal cell degeneration in both these conditions. Therefore, central, rather than peripheral, vision loss is progressively compromised over time, and is the chief source of vision-related disability and healthcare-seeking behavior in both conditions. We selected SHL as another control because it is the impairment of a sensory system, other than vision, that affects younger individuals and entails long-term healthcare cost implications. Therefore, the aim of this study was to estimate the direct healthcare costs of SD as compared to non-exudative AMD and SHL.

Methods

Data Source

Outpatient insurance claims data from 2010 to 2014 were analyzed using the IBM® MarketScan® Commercial Claims and Encounters Database. MarketScan® is a large database containing adjudicated and paid insurance claims data of individuals and their dependents whose health insurance is provided by their employers. These include active employees, early retirees and Consolidated Omnibus Budget Reconciliation Act (COBRA) continuers. Most of the data are collected from large employers and health plans. The types of benefit plans include comprehensive, exclusive provider organization (EPO), health maintenance organization (HMO), preferred provider organization (PPO), consumer directed health plan (CDHP), high deductible health plan (HDHP) and point-of-service (POS) plans with and without capitation. A unique identifier assigned to each patient is coded on claims. The dataset complies with Health Insurance Portability and Accountability Act regulations for a limited data-set and has undergone a third

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

party review for a fully de-identified dataset¹¹. The study was approved by the Johns Hopkins Medicine Institutional Review Board. Study Population Claims with a primary diagnosis of SD, SHL and AMD were selected using ICD-9 diagnosis codes 362.75, 389.18 and 362.51, respectively. Claims with missing procedure codes were excluded. The unique patient identifier coded on claims was used to associate claims to each patient. In cases where a patient had more than one diagnosis, the primary diagnosis was used for categorization. Patients aged <50 years with a diagnosis of AMD were assumed to have been misdiagnosed or mis-coded and so were excluded from analysis. SHL patients with cochlear implants were excluded due to lack of a comparable device to improve function in SD. Patients with exudative AMD, cystoid macular degeneration, macular cyst, hole or pseudohole, macular pucker or toxic maculopathy were excluded. Statistical Analyses The gross median payments to providers for health services per year of insurance coverage were calculated for SD, SHL and AMD. We accounted for periods of non-coverage by considering only the total number of insured days for each patient. Categorical variables were reported as frequencies and percentages while continuous variables were reported as medians with interquartile ranges. The Wilcoxon rank-sum test was used to test for statistical differences in the number of insurance claims per covered year and payments per covered year between groups. A multivariable quantile regression was used to adjust for covariates and analyze payments per covered year for each condition. Furthermore, a multivariable quantile regression model was used to compare payments per covered year between SD and SHL.

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

Additional multivariable regression models were used to compare payments per covered year for SD with patients restricted to those aged ≥ 50 years and AMD for a more effective comparison. Covariates selected for the regression models included age (continuous variable), gender (male or female), year of first service in the database (2010-2014) and type of benefit plans (PPO, comprehensive, HMO, PPO with and without capitation, POS, CDHP and HDHP). The covariates were categorized as in the database. A two-tailed P value of <0.05 was considered to be statistically significant. All statistical analyses were performed using Stata/MP version 14.2 (StataCorp LLC, College Station, TX). **Results** Population Characteristics A total of 472,428 patients were analyzed (Table 1). Of these were 5,015 (1.1%) patients with SD, 369,750 (78.3%) with SHL, and 97,663 (20.7%) with AMD. Patients with SD (median age: 41 years, IQR [interquartile range]: 23-53 years) were younger than those with SHL (median age: 54 years, IQR: 44-60 years, p <0.001), and AMD (median age: 60 years, IQR: 56-62 years, p <0.001). The majority of SD and AMD patients were female (55.0% and 58.9%, respectively), whereas the majority of SHL patients were male (53.0%). The mean total number of gaps in insurance coverage per patient was 0.13 ± 0.41 . Healthcare utilization The number of insurance claims per year for SD patients (median: 0.51, IQR: 0.33-1.00) was greater than in SHL (median: 0.40, IQR: 0.25-0.67, p < 0.001) and in AMD (median: 0.50, IQR:

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

0.32-1.00, p <0.001). The most common healthcare service utilized for SD patients was fundus photography (n=2,614, 11.98%). Medical examination and evaluation (n=57,950, 15.32%) was the most common healthcare service in AMD. Comprehensive audiometry threshold evaluation and speech recognition (n=308,619, 27.42%) was the most common healthcare service in SHL. Table 2 details the top five services utilized in each group. Healthcare costs Payments per year for SD (median [IQR], \$105.58 [\$50.53-\$218.71]) were greater than for SHL (\$51.01 [\$25.66-\$121.66], p <0.001) and AMD (\$76.20 [\$38.00-\$164.86], p <0.001). Table 3 presents the regression analysis for payments for each condition, adjusting for age, sex, type of benefit plan and year of first service. For SD patients, female gender was associated with higher annual payments as compared to males (p=0.03). However, older age (per year) was associated with lower payments of \$0.75 per year. Annual payments varied by type of plan (HMO \$15.73 lower than PPO, p=0.012). For SHL, EPO plans were associated with higher payments per year (\$6.99) than PPO plans (p<0.001). Factors associated with lower payments included higher age, female gender, year of first service in the database (2011-2014), and type of plan. For AMD, older age (per year) was associated with an additional \$1.60 payment (p<0.001). Payments for females were \$3.22 higher than those for males (p<0.001). Those with POS with capitation plans incurred \$10.02 more per year than those with PPO plans (p=0.014). When comparing payments per year for SD to those for SHL, adjusted payments per year were significantly higher for SD patients (Table 4). The adjusted median payments for SD was \$ 101.06 (95% confidence interval [CI]: \$ 98.92-\$ 103.20) and \$53.23 (95%CI: \$52.98-\$53.48) for SHL.

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

The difference in payments per year was \$47.83 (95% CI: \$45.67 - \$49.98, p<0.001). EPO plans were associated with higher payments per covered year. Because of the age difference in SD and AMD patients, we also compared the AMD data with that of SD patients aged \geq 50 years (n=1,669) (Table 5). A similar trend in the result was observed. The adjusted median payment for SD patients aged ≥50 years was \$96.43 (95%CI: \$91.35-\$101.51) and was \$79.09 (95%CI: \$78.43-\$79.74) for AMD. Therefore, payments for SD patients were \$17.34 higher than for AMD (95% CI: \$12.22 - \$22.47, p<0.001). Factors associated with significantly greater payments included older age, female gender, and type of benefit plan (POS with capitation). **Discussion** The data show that there is a significant annual healthcare cost associated with SD. Payments associated with SD were higher than two control conditions, SHL and AMD. Payments also appeared to be influenced by patient gender, possibly due to differences in gender-related disease progression¹² or health-seeking behavior¹³. To our knowledge, this is the first published estimate of the direct healthcare costs associated with SD. The annual unadjusted median cost for patients with SD in our study, using only the MarketScan commercial claims and encounters database, was \$105.58. A prior study estimated the healthcare costs of retinitis pigmentosa (RP), another inherited degenerative retinal disease, to be \$3206 per patient¹⁴. This is higher than the figure reported by our study. This difference could be related to the fact that the RP study included both the MarketScan® commercial claims and encounters and the Medicare supplemental datasets. Also, the RP study included claims with an ICD-9 diagnosis

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

of retinitis pigmentosa in both the primary or secondary diagnosis position. In this study, we limited the analyzed claims to those with a primary diagnosis of SD. While limiting the dataset, this enhances the specificity of results to SD-related healthcare encounters. Future studies on the costs of SD could integrate multiple datasets to see if the SD-related costs are comparable to those of RP. Greater awareness of the economic burden of SHL and AMD exists possibly because of their higher prevalence than SD. In one study which used Medicare data, the annual per-patient cost for dry AMD was reported to be \$204.43⁸, a higher amount than we found. This difference could be due to the use of a different database, with an older population. A study from United Kingdom, including children aged 7 to 9 years with congenital bilateral hearing impairment, reported an annual per-patient healthcare cost of \$2808, again higher than in our data. The study only included children with over 60 dB hearing loss, relied mostly on self-reported cost information from parents, included costs related to inpatient care and the use of community and social care services, as well as the cost of cochlear implants, hearing aids, and other assistive devices such as loop systems and special alarm clocks^{15,16}. One of the potential factors driving the high total healthcare costs for SD is the relatively early onset of disease. SD is usually diagnosed in the second or third decades of life and the associated visual loss is progressive thereafter. The total direct costs of diseases that present at an early age could be higher than diseases that present later, due to accumulation of costs over time. While this study does not address the impact of the disease on productivity and quality of life, one can extrapolate that a disease with onset at earlier ages would lead to a greater lifetime impact on productivity and quality of life than diseases that occur in late life. Vision impairment has a significant impact on education, employment, productivity, and independence of daily living.

Vision impairment is also associated with falls, injuries, reduced mobility, depression, poor health outcomes, and reduced quality of life¹⁷. One study reported that the total economic burden, including direct and indirect costs, was \$27.5 billion per year (2012 dollars) among people aged 40 years and younger with eye disorders¹⁸. Estimates of the total economic burden of SD, and its indirect costs, are not yet available. This study has several limitations. First, the data were limited to patients younger than 65 years. Therefore, the overall costs might be under-reported for AMD. Second, the dataset used for the current study does not include Medicare and Medicaid data, and therefore these costs are not included. Third, individuals who are uninsured or unemployed were not captured in the MarketScan database, because it includes only employment-based claims. Fourth, since there is no treatment available for SD, a vast majority of the patients rely on low vision devices, especially in the later stages of the disease¹⁹. These low vision devices are not covered by many insurance companies in the United States and therefore the associated cost was not fully captured herein. Further, the nature of any administrative claims database is such that there is a possibility of diagnosis and procedure codes not being recorded in a standardized way. Lastly, disease stage or severity was not considered in this study. Further research could explore other datasets, and include the costs attributable to low vision aids, guide dogs, loss of productivity, reduction in hours worked, and caregiver costs. It would also be useful to evaluate visual function and disease severity in relation to economic impact. The development of novel therapeutic modalities such as retinal stem cell and gene therapy^{3,20–27} are likely to affect the long-term economic burden associated with SD.

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

Conclusion

In this limited dataset, the annual per-patient costs of SD were found to be higher than those incurred by patients with bilateral SHL and non-exudative AMD. The total lifetime per-patient cost of SD may exceed that of non-exudative AMD, due to the earlier age of onset of the former condition. There is a need to develop cost-effective treatments for SD, to reduce the long-term economic burden associated with this condition.

References

- 241 1. Walia S, Fishman GA. Natural history of phenotypic changes in Stargardt macular dystrophy. Ophthalmic Genet. 2009;30(2):63-68. doi:10.1080/13816810802695550 242
- 243 2. Haji Abdollahi S, Hirose T. Stargardt-Fundus flavimaculatus: recent advancements and treatment. Semin Ophthalmol. 2013;28(5-6):372-376. doi:10.3109/08820538.2013.825286 244
- 245 3. Lu LJ, Liu J, Adelman RA. Novel therapeutics for Stargardt disease. Graefes Arch Clin Exp 246 Ophthalmol. 2017;255(6):1057-1062. doi:10.1007/s00417-017-3619-8
- 247 Auricchio A, Trapani I, Allikmets R. Gene Therapy of ABCA4-Associated Diseases. Cold 4. Spring Harb Perspect Med. 2015;5(5):a017301. doi:10.1101/cshperspect.a017301 248
- 249 Tanna P, Strauss RW, Fujinami K, Michaelides M. Stargardt disease: clinical features,
- molecular genetics, animal models and therapeutic options. British Journal of 250
- Ophthalmology. August 2016:bjophthalmol-2016-308823. doi:10.1136/bjophthalmol-2016-251
- 252 308823
- 253 Armstrong JD, Meyer D, Xu S, Elfervig JL. Long-term follow-up of Stargardt's disease and
- 254 fundus flavimaculatus. Ophthalmology. 1998;105(3):448-457; discussion 457-458.
- 255 doi:10.1016/S0161-6420(98)93026-3
- 256 7. Westeneng-van Haaften SC, Boon CJF, Cremers FPM, Hoefsloot LH, den Hollander AI,
- Hoyng CB. Clinical and genetic characteristics of late-onset Stargardt's disease. 257
- 258 Ophthalmology. 2012;119(6):1199-1210. doi:10.1016/j.ophtha.2012.01.005
- Halpern MT, Schmier JK, Covert D, Venkataraman K. Resource utilization and costs of 259 8. 260 age-related macular degeneration. Health Care Financ Rev. 2006;27(3):37-47.
- Schmier JK, Jones ML, Halpern MT. The burden of age-related macular degeneration. 261 9.
- 262 Pharmacoeconomics. 2006;24(4):319-334.
- 10. Macular Degeneration Treatment Market Size, Share, Trends | Forecast 2026. 263
- 264 https://www.acumenresearchandconsulting.com/macular-degeneration-treatment-market.
- Accessed May 10, 2019. 265
- 11. Hansen L. The Truven Health MarketScan Databases for life sciences researchers. :24. 266
- Zahid S, Jayasundera T, Rhoades W, et al. Clinical phenotypes and prognostic full-field 267
- electroretinographic findings in Stargardt disease. Am J Ophthalmol. 2013;155(3):465-268
- 473.e3. doi:10.1016/j.ajo.2012.09.011 269
- 270 13. Bertakis KD, Azari R, Helms LJ, Callahan EJ, Robbins JA. Gender differences in the
- utilization of health care services. J Fam Pract. 2000;49(2):147-152. 271

- 272 14. Frick KD, Roebuck MC, Feldstein JI, McCarty CA, Grover LL. Health services utilization
- and cost of retinitis pigmentosa. Arch Ophthalmol. 2012;130(5):629-634.
- doi:10.1001/archophthalmol.2011.2820
- 275 15. Schroeder L, Petrou S, Kennedy C, et al. The economic costs of congenital bilateral
- permanent childhood hearing impairment. *Pediatrics*. 2006;117(4):1101-1112.
- doi:10.1542/peds.2005-1335
- 278 16. World Health Organization. Global Costs of Unaddressed Hearing Loss and Cost-
- 279 Effectiveness of Interventions.; 2017.
- 280 http://apps.who.int/iris/bitstream/10665/254659/1/9789241512046-eng.pdf. Accessed
- 281 September 16, 2019.
- 282 17. Read "Making Eye Health a Population Health Imperative: Vision for Tomorrow" at
- 283 *NAP.Edu.* doi:10.17226/23471
- 18. Wittenborn JS, Zhang X, Feagan CW, et al. The economic burden of vision loss and eye
- disorders among the United States population younger than 40 years. *Ophthalmology*.
- 286 2013;120(9):1728-1735. doi:10.1016/j.ophtha.2013.01.068
- 287 19. Collee CM, Jalkh AE, Weiter JJ, Friedman GR. Visual Improvement with Low Vision Aids
- in Stargardt's Disease. Ophthalmology. 1985;92(12):1657-1659. doi:10.1016/S0161-
- 289 6420(85)34086-1
- 290 20. Schwartz SD, Hubschman J-P, Heilwell G, et al. Embryonic stem cell trials for macular
- degeneration: a preliminary report. *Lancet*. 2012;379(9817):713-720. doi:10.1016/S0140-
- 292 6736(12)60028-2
- 293 21. Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal
- 294 pigment epithelium in patients with age-related macular degeneration and Stargardt's
- 295 macular dystrophy: follow-up of two open-label phase 1/2 studies. *Lancet*.
- 296 2015;385(9967):509-516. doi:10.1016/S0140-6736(14)61376-3
- 22. Schwartz SD, Tan G, Hosseini H, Nagiel A. Subretinal Transplantation of Embryonic Stem
- 298 Cell-Derived Retinal Pigment Epithelium for the Treatment of Macular Degeneration: An
- Assessment at 4 Years. *Invest Ophthalmol Vis Sci.* 2016;57(5):ORSFc1-9.
- 300 doi:10.1167/iovs.15-18681
- 301 23. Song WK, Park K-M, Kim H-J, et al. Treatment of Macular Degeneration Using
- 302 Embryonic Stem Cell-Derived Retinal Pigment Epithelium: Preliminary Results in Asian
- 303 Patients. Stem Cell Reports. 2015;4(5):860-872. doi:10.1016/j.stemcr.2015.04.005
- 304 24. Hussain RM, Ciulla TA, Berrocal AM, Gregori NZ, Flynn HW, Lam BL. Stargardt macular
- 305 dystrophy and evolving therapies. *Expert Opin Biol Ther*. 2018;18(10):1049-1059.
- 306 doi:10.1080/14712598.2018.1513486

da Cruz L, Fynes K, Georgiadis O, et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. *Nat Biotechnol*. 2018;36(4):328-337. doi:10.1038/nbt.4114
De Silva SR, Charbel Issa P, Singh MS, et al. Single residue AAV capsid mutation improves transduction of photoreceptors in the Abca4-/- mouse and bipolar cells in the rd1

mouse and human retina ex vivo. Gene Ther. 2016;23(11):767-774. doi:10.1038/gt.2016.54

313 27. McClements ME, Barnard AR, Singh MS, et al. An AAV Dual Vector Strategy 314 Ameliorates the Stargardt Phenotype in Adult Abca4-/- Mice. *Hum Gene Ther*. 315 2019;30(5):590-600. doi:10.1089/hum.2018.156

316 Tables

317

318

319

320

321

Table 1. General characteristics of the study population

Characteristics	SD	SHL	AMD
	(N=5,015)	(N=369,750)	(N=97,663)
Age, median (IQR) yrs	41 (23 - 53)	54 (44 - 60)	60 (56 - 62)
Sex, no. (%)			
Male	2,257 (45.00)	196,011 (53.01)	40,186 (41.15)
Female	2,758 (55.00)	173,739 (46.99)	57,477 (58.85)
Type of benefit plan, no. (%)	n=4,600	n=334,156	n=87,576
PPO	98 (2.13)	8,891 (2.66)	3,574 (4.08)
Comprehensive	157 (3.41)	9,026 (2.70)	2,228 (2.54)
EPO	538 (11.70)	42,979 (12.86)	7,918 (9.04)
НМО	336 (7.30)	25,916 (7.76)	7,211 (8.23)
POS	3,036 (66.00)	215,970 (64.63)	59,372 (67.79)
POS with capitation	28 (0.61)	2,084 (0.62)	605 (0.69)
CDHP	209 (4.54)	16,947 (5.07)	3,965 (4.53)
HDHP	198 (4.30)	12,343 (3.69)	2,703 (3.09)

SD: stargardt disease, SHL: bilateral sensorineural hearing loss, AMD: non-exudative age related macular degeneration, IQR: interquartile range, PPO: preferred provider organization, EPO: exclusive provider organization, HMO: health maintenance organization, POS: point-of-service, CDHP: consumer directed health plan, HDHP: high deductible health plan

Table 2. Most common healthcare services utilized

Healthcare service/CPT code	N (%)
SD	
Fundus photography (92250)	2,614 (11.98)
Medical examination and evaluation (92014)	2,343 (10.74)
Scanning computerized ophthalmic diagnostic imaging of the retina (92134)	1,994 (9.14)
Fluorescein angiography (92235)	1,329 (6.09)
Extended ophthalmoscopy (new visit or diagnosis) (92226)	1,215 (5.57)
SHL	
Comprehensive audiometry threshold evaluation and speech recognition (92557)	308,619 (27.42)
Tympanometry (impedance testing) (92567)	181,190 (16.10)
Tympanometry and reflex threshold measurements (92550	66,965 (5.95)
Office visit-established patient (99213)	54,304 (4.83)
Office visit-new patient (99203)	34,838 (3.10)
AMD	
Medical examination and evaluation (92014)	57,950 (15.32)
Fundus photography (92250)	51,245 (13.55)
Scanning computerized ophthalmic diagnostic imaging of the retina	50,508 (13.35)
(92134)	
Extended ophthalmoscopy (new visit or diagnosis) (92226)	27,246 (7.20)
Fluorescein angiography (92235)	21,472 (5.68)

³²³ CPT: current procedural terminology, SD: stargardt disease, SHL: bilateral sensorineural hearing loss,

³²⁴ AMD: non-exudative age related macular degeneration

Table 3. Multivariable quantile regression for payments per covered year

Stargardt disease		
Variables	Coefficient (95% CI)	P-value
Age	-0.75 (-0.98, -0.53)	0.001
Sex		
Male	Reference	
Female	8.82 (0.98, 16.67)	0.03
Year service was rendered		
2010	Reference	
2011	-29.61 (-40.90, -18.32)	< 0.001
2012	-41.52 (-53.22, -29.81)	< 0.001
2013	-26.83 (-38.91, -14.74)	< 0.001
2014	-27.24 (-39.52, -14.96)	< 0.001
Type of benefit plan		
PPO	Reference	
Comprehensive	7.25 (-19.81, 34.31)	0.599
EPO	-6.22 (-27.79, 15.34)	0.572
НМО	-15.73 (-28.06, -3.40)	0.012
POS	-1.60 (-16.76, 13.56)	0.836
POS with capitation	28.66 (-21.34, 78.66)	0.261
CDHP	10.41 (-8.44, 29.26)	0.279
HDHP	6.81 (-12.53, 26.15)	0.490
Bilateral sensorineural hearing los	S	
Variables State of the state of	Coefficient (95% CI)	P-value
Age	-0.32 (-0.34, -0.31)	< 0.001
Sex	· · ·	
Male	Reference	
Female	-3.62 (-4.11, -3.12)	< 0.001
Year service was rendered		
2010	Reference	
2011	-16.30 (-17.07, -15.53)	< 0.001
2012	-20.54 (-21.31, -19.77)	< 0.001
2013	-18.11 (-18.89, -17.32)	< 0.001
2014	-12.65 (-13.43, -11.87)	< 0.001
Type of benefit plan	<u> </u>	
PPO	Reference	
Comprehensive	-1.87 (-3.41, -0.32)	0.018
EPO	6.99 (5.45, 8.52)	< 0.001
HMO	-4.17 (-4.93,-3.42)	<0.001
POS	-1.92 (-2.86, -0.98)	< 0.001
POS with capitation	-1.35 (-4.49, 1.80)	0.402
CDHP	-2.61 (-3.75, -1.47)	<0.001
HDHP	0.26 (-1.06, 1.58)	0.701
	, , ,	0.701
Nonexudative age-related macular		
Nonexudative age-related macular Variables	Coefficient (95% CI)	P-value

Sex		
Male	Reference	
Female	3.03 (1.69, 4.36)	< 0.001
Year service was rendered		
2010	Reference	
2011	-38.54 (-40.48, -36.59)	< 0.001
2012	-48.88 (-50.87, -46.89)	< 0.001
2013	-47.87 (-49.89, -45.84)	< 0.001
2014	-51.77 (-53.82, -49.72)	< 0.001
Type of benefit plan		
PPO	Reference	
Comprehensive	-14.68 (-18.04, -11.31)	< 0.001
EPO	1.97 (-2.23, 6.17)	0.357
НМО	-4.56 (-6.88, -2.23)	< 0.001
POS	-0.62 (-3.05, 1.81)	0.615
POS with capitation	10.02 (2.07, 17.96)	0.014
CDHP	-9.22 (-12.41, -6.03)	< 0.001
HDHP	1.72 (-2.11, 5.55)	0.378

CI: confidence interval, PPO: preferred provider organization, EPO: exclusive provider organization,

HMO: health maintenance organization, POS: point-of-service, CDHP: consumer directed health plan,

328 HDHP: high deductible health plan

326

Table 4. Payments per covered year for SD vs. SHL

329

330

331332

Variables	Coefficient (95% CI)	P-value
Condition		
SD	Reference	
SHL	-47.83 (-49.98, -45.67)	< 0.001
Age	-0.33 (-0.34, -0.31)	< 0.001
Sex		
Male	Reference	
Female	-3.57 (-4.07, -3.07)	< 0.001
Year service was rendered		
2010	Reference	
2011	-16.40 (-17.17, -15.63)	< 0.001
2012	-20.67 -21.44, -19.89)	< 0.001
2013	-18.21 (-18.99, -17.42)	< 0.001
2014	-12.76 (-13.55, -11.97)	< 0.001
Type of benefit plan		
PPO	Reference	
Comprehensive	-1.73 (-3.30, -0.17)	0.030
EPO	6.81 (5.27, 8.35)	< 0.001
НМО	-4.23 (-4.99, -3.47)	< 0.001
POS	-1.93 (-2.88, -0.99)	< 0.001
POS with capitation	-1.13 (-4.30, 2.03)	0.483
CDHP	-2.54 (-3.69, -1.39)	< 0.001
HDHP	0.28 (-1.05, 1.61)	0.676

CI: confidence interval, SD: stargardt disease, SHL: bilateral sensorineural hearing loss, PPO: preferred provider organization, EPO: exclusive provider organization, HMO: health maintenance organization,

POS: point-of-service, CDHP: consumer directed health plan, HDHP: high deductible health plan

Table 5. Payments per covered year for SD vs. AMD

Variables	Coefficient (95% CI)	P-value
Condition		
SD	Reference	
AMD	-17.34 (-22.47, -12.22)	< 0.001
Age	1.58 (1.42, 1.74)	< 0.001
Sex		
Male	Reference	
Female	3.04 (1.71, 4.37)	< 0.001
Year service was rendered		
2010	Reference	
2011	-38.51 (-40.44, -36.59)	< 0.001
2012	-48.74 (-50.72, -46.76)	< 0.001
2013	-47.71 (-49.73, -45.70)	< 0.001
2014	-51.59 (-53.62, -49.55)	< 0.001
Type of benefit plan		
PPO	Reference	
Comprehensive	-14.79 (-18.14, -11.44)	< 0.001
EPO	1.97 (-2.21, 6.14)	0.356
НМО	-4.79 (-7.10, -2.48)	< 0.001
POS	-0.70 (-3.11, 1.72)	0.571
POS with capitation	9.84 (1.92, 17.76)	0.015
CDHP	-8.80 (-11.97, -5.62)	< 0.001
HDHP	1.97 (-1.83, 5.78)	0.309

CI: confidence interval, SD: stargardt disease, AMD: non-exudative age related macular degeneration, PPO: preferred provider organization, EPO: exclusive provider organization, HMO: health maintenance organization, POS: point-of-service, CDHP: consumer directed health plan, HDHP: high deductible health plan